Skip to main content
Contact Us
Subscriber Sign In
navigation
サイト内検索
What We Do
Commercial Intelligence
Products
Evaluate Pharma
Evaluate Omnium
Evaluate Medtech
Evaluate Epi
Japan Drug Forecasts
Europe Drug Forecasts
CDMO Intelligence
Real World Data
Pharma Consulting & Analytics
Pharma Consulting & Analytics
Data Feeds
Evaluate Vantage
News
Analysis
Policy & Pricing
Insights
Events
Medtech
Therapy Areas
Evaluate for Biotech
How We Can Help You
Pharma and Biotech
Financial Services
Management Consultancies
Service Providers
Customer Testimonials
Thought Leadership
Multimedia
Blog
About Us
Press Releases
Media Coverage
Executive Team
Vision & History
Contact Us
Sign Up for Evaluate Vantage
Talent
Subscriber Sign In
Search
Open configuration options
Search
Vantage
News
Snippets
Deals
Trial results
Patents and litigation
Corporate strategy
Analysis
Interviews
Spotlight
Vantage points
Vantage views
Insights
M&A
IPO
NME approvals
Quarterly shareprice performance
Venture financing
Vantage data points
Other data
Events
Company events
Conferences
Upcoming events
Medtech
Therapy Areas
Breadcrumb
Home
Vantage
Pharmaceutical Companies
Theratechnologies
Evaluate
March 07, 2018
HIV approval thrusts Theratechnologies into the limelight
May 07, 2013
Lipodystrophy could give metreleptin a new lease of life
January 09, 2013
Sarepta joins the big league as best-performing 2012 share
October 10, 2012
Wockardt and Arena lead small-cap gainers through nine months
July 04, 2012
Obesity turnaround drives small cap gainers in H1
December 13, 2010
Somatropin safety review highlights lack of alternatives
November 11, 2010
Theratechnologies looking global after Egrifta US approval
September 28, 2010
EP Vantage Interview - On top of market gains Bionor awaits trial results
May 28, 2010
Theratechnologies defies doubts and gets OK from FDA adcom
May 12, 2010
Event - Theratechnologies hopes adcom will stimulate growth in more than one way
November 27, 2008
One-product companies currently on a knife edge
Load More
Latest Reports
July 27, 2023
H1 Round Up: The haves and the have-nots
July 21, 2023
ADA/EASL eBook
Editor's Picks
July 03, 2023
Astrazeneca and Daiichi’s big reveal disappoints
July 13, 2023
Pharma finds a way to gain weight
July 03, 2023
Protagonist investors flake as psoriasis pill disappoints
June 29, 2023
Approaching datasets for big pharma
June 27, 2023
Nkarta goes back to basics